Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
Although treatment options in breast cancer have been improved significantly, predictive biomarkers for disease progression and metastasis are still lacking. Recent studies indicate that several TNF Receptor Superfamily members are involved in breast cancer cell proliferation and survival. Interesti...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.642170/full |
| _version_ | 1818677438106828800 |
|---|---|
| author | Clemens Hinterleitner Clemens Hinterleitner Yanjun Zhou Yanjun Zhou Claudia Tandler Claudia Tandler Jonas S. Heitmann Jonas S. Heitmann Korbinian N. Kropp Martina Hinterleitner Martina Hinterleitner André Koch Andreas D. Hartkopf Lars Zender Lars Zender Lars Zender Helmut R. Salih Helmut R. Salih Stefanie Maurer Stefanie Maurer Stefanie Maurer |
| author_facet | Clemens Hinterleitner Clemens Hinterleitner Yanjun Zhou Yanjun Zhou Claudia Tandler Claudia Tandler Jonas S. Heitmann Jonas S. Heitmann Korbinian N. Kropp Martina Hinterleitner Martina Hinterleitner André Koch Andreas D. Hartkopf Lars Zender Lars Zender Lars Zender Helmut R. Salih Helmut R. Salih Stefanie Maurer Stefanie Maurer Stefanie Maurer |
| author_sort | Clemens Hinterleitner |
| collection | DOAJ |
| description | Although treatment options in breast cancer have been improved significantly, predictive biomarkers for disease progression and metastasis are still lacking. Recent studies indicate that several TNF Receptor Superfamily members are involved in breast cancer cell proliferation and survival. Interestingly, TNFRSF13B (TACI) mRNA level were of prognostic relevance in breast cancer patients. In this study we provide evidence for TACI expression on platelets of breast cancer patients. The level of platelet-expressed TACI (pTACI) was significantly increased on platelets derived from breast cancer patients compared to healthy controls. Upon platelet activation, pTACI was downregulated on the platelet surface of healthy donors and breast cancer patients. Of note, inhibition of matrix metalloprotease (MMP) prevented downregulation of pTACI ex vivo, indicating that proteolytic cleavage of pTACI is responsible for reduction of pTACI level. Stimulation of pTACI via BAFF, BAFF 60-mer or APRIL did not influence platelet activation and function. Remarkably, pTACI was particularly regulated during tumor progression in our breast cancer cohort. TACI expression levels on platelets were correlated with clinical parameters including tumor stage, occurrence of metastasis and tumor cell proliferation (Ki67). In conclusion, our data emphasize the potential use of platelets as a liquid biomarker in breast cancer. |
| first_indexed | 2024-12-17T08:59:22Z |
| format | Article |
| id | doaj.art-f1e066b6d9144fb291563d5bed57ea7b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T08:59:22Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f1e066b6d9144fb291563d5bed57ea7b2022-12-21T21:55:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.642170642170Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer ProgressionClemens Hinterleitner0Clemens Hinterleitner1Yanjun Zhou2Yanjun Zhou3Claudia Tandler4Claudia Tandler5Jonas S. Heitmann6Jonas S. Heitmann7Korbinian N. Kropp8Martina Hinterleitner9Martina Hinterleitner10André Koch11Andreas D. Hartkopf12Lars Zender13Lars Zender14Lars Zender15Helmut R. Salih16Helmut R. Salih17Stefanie Maurer18Stefanie Maurer19Stefanie Maurer20Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Hematology, Medical Oncology and Pneumology, University Medical Center of Mainz, Mainz, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyDepartment of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Obstetrics and Gynecology, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyGerman Cancer Research Consortium (DKTK), Partner Site Tübingen, German Cancer Research Center (DKFZ), Heidelberg, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, GermanyClinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, GermanyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesAlthough treatment options in breast cancer have been improved significantly, predictive biomarkers for disease progression and metastasis are still lacking. Recent studies indicate that several TNF Receptor Superfamily members are involved in breast cancer cell proliferation and survival. Interestingly, TNFRSF13B (TACI) mRNA level were of prognostic relevance in breast cancer patients. In this study we provide evidence for TACI expression on platelets of breast cancer patients. The level of platelet-expressed TACI (pTACI) was significantly increased on platelets derived from breast cancer patients compared to healthy controls. Upon platelet activation, pTACI was downregulated on the platelet surface of healthy donors and breast cancer patients. Of note, inhibition of matrix metalloprotease (MMP) prevented downregulation of pTACI ex vivo, indicating that proteolytic cleavage of pTACI is responsible for reduction of pTACI level. Stimulation of pTACI via BAFF, BAFF 60-mer or APRIL did not influence platelet activation and function. Remarkably, pTACI was particularly regulated during tumor progression in our breast cancer cohort. TACI expression levels on platelets were correlated with clinical parameters including tumor stage, occurrence of metastasis and tumor cell proliferation (Ki67). In conclusion, our data emphasize the potential use of platelets as a liquid biomarker in breast cancer.https://www.frontiersin.org/articles/10.3389/fonc.2021.642170/fullbreast cancerplateletsbiomarkermetastasisTACI/TNFRSF13Bcancer |
| spellingShingle | Clemens Hinterleitner Clemens Hinterleitner Yanjun Zhou Yanjun Zhou Claudia Tandler Claudia Tandler Jonas S. Heitmann Jonas S. Heitmann Korbinian N. Kropp Martina Hinterleitner Martina Hinterleitner André Koch Andreas D. Hartkopf Lars Zender Lars Zender Lars Zender Helmut R. Salih Helmut R. Salih Stefanie Maurer Stefanie Maurer Stefanie Maurer Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression Frontiers in Oncology breast cancer platelets biomarker metastasis TACI/TNFRSF13B cancer |
| title | Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression |
| title_full | Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression |
| title_fullStr | Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression |
| title_full_unstemmed | Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression |
| title_short | Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression |
| title_sort | platelet expressed tnfrsf13b taci predicts breast cancer progression |
| topic | breast cancer platelets biomarker metastasis TACI/TNFRSF13B cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.642170/full |
| work_keys_str_mv | AT clemenshinterleitner plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT clemenshinterleitner plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT yanjunzhou plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT yanjunzhou plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT claudiatandler plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT claudiatandler plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT jonassheitmann plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT jonassheitmann plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT korbiniannkropp plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT martinahinterleitner plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT martinahinterleitner plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT andrekoch plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT andreasdhartkopf plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT larszender plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT larszender plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT larszender plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT helmutrsalih plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT helmutrsalih plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT stefaniemaurer plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT stefaniemaurer plateletexpressedtnfrsf13btacipredictsbreastcancerprogression AT stefaniemaurer plateletexpressedtnfrsf13btacipredictsbreastcancerprogression |